阿托伐他汀联合曲美他嗪治疗冠心病临床疗效观察(1)
【摘要】目的 总结阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效。方法 对2015年4月～2018年1月间符合纳入标准的冠心病患者60例展开对比分析，以数字表随机原则分对照组30例给予单用曲美他嗪治疗，研究组30例则给予阿托伐他汀与曲美他嗪的联合方案治疗，比较两组患者治疗效果。结果 研究组治疗总有效率90.91%(28)明显高于对照组63.64%(22)，两组差异具有统计学意义(P<0.05)；研究组左室舒张末期内径(LVEDD)与收缩末期内径(LVESD)等心功能指标水平明显低于对照组，差异具有统计学意义(P<0.05)。结果 阿托伐他汀联合曲美他嗪应用于治疗冠心病中确可获得满意效果，有助于改善患者心功能，值得临床推广应用。
【关键词】阿托伐他汀；曲美他嗪；冠心病；疗效
【中图分类号】R541.4 【文献标识码】A 【文章编号】ISSN.2095.6681.2018.06.16..02
【Abstract】Objective To summarize the clinical efficacy of Atorvastatin Combined with trimetazidine in the treatment of coronary heart disease.Methods From April 2015 to January 2018， 60 cases of coronary heart disease were compared and analyzed in accordance with the inclusion criteria.30 cases in the control group were given single use of trimetazidine， and 30 cases in the study group were given the combined regimen of atorvastatin and trimetazidine in the study group， and the treatment effect of the two groups were compared.Results The total effective rate of treatment in the study group was 90.91%(28) significantly higher than that of the control group 63.64%(22)，and the two groups were statistically significant (P<0.05).The level of left ventricular end diastolic diameter (LVEDD) and the end systolic diameter(LVESD) in the study group were significantly lower than those in the control group(P<0.05).Conclusion Atorvastatin Combined with trimetazidine can achieve satisfactory results in the treatment of coronary heart disease.It is helpful to improve the cardiac function of the patients and is worthy of clinical application.
【Key words】Atorvastatin；Trimetazidine；Coronary heart disease；Curative effect.
冠心病(coronary atherosclerotic heart disease，CHD)是一組临床常见综合征，病理机制主要为冠状动脉解剖结构或功能异常形成的心肌缺血、梗死。药物干预是治疗本病主要手段，较常规单药治疗方案不同，现阶段强调药理的协同作用，但就具体药物的选择尚无统一标准[1]。本文对60例符合纳入标准的冠心病患者展开对比分析，总结阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效，旨在为临床提供参考，总结如下。
1 资料与方法
1.1 一般资料
对符合纳入标准的2015年4月～2018年1月冠心病患者60例展开对比分析；本组患者入院均行相关检查，符合国际心脏病学会、WHO联合制定的《缺血性心脏病命名及诊断标准》中相关标准；男32例，女28例，年龄46～80岁，平均年龄(61.35±7.41)岁，病程1～20年，平均病程(7.33±0.41)年，体质量53～74 kg，平均(60.15±5.10)kg；两组患者基线资料差异无统计学意义(P>0.05)。
1.2 方法
患者入院后均给予吸氧、扩血管药物、利尿剂等基础治疗；对照组在此基础上给予盐酸曲美他嗪片(泽维尔)(生产厂家：北京万生药业有限责任公司；批准文号：国药准字H20065167)20 mg/次，每日3次；研究组在对照组基础上给予立普妥(阿托伐他汀钙片)(生产厂家：辉瑞制药有限公司；批准文号：国药准字H20051408)
10 mg/次，每日1次。
1.3 疗效判定标准
疗效：依据我国《心血管药物临床试验评价方法的建议》[2]中相关诊断标准评估疗效：显效为患者治疗后超过7 d未感心绞痛，ST段明显回升，导联T波变浅超过50%；有效为患者心绞痛发作频率明显减少，心电图ST段明显改善；无效为达不到上述标准；总有效率=显效率+有效率；
采用心脏彩色超声对患者左室舒张末期内径(LVEDD)与收缩末期内径(LVESD)等心功能指标。, http://www.100md.com(王卫平)
【关键词】阿托伐他汀；曲美他嗪；冠心病；疗效
【中图分类号】R541.4 【文献标识码】A 【文章编号】ISSN.2095.6681.2018.06.16..02
【Abstract】Objective To summarize the clinical efficacy of Atorvastatin Combined with trimetazidine in the treatment of coronary heart disease.Methods From April 2015 to January 2018， 60 cases of coronary heart disease were compared and analyzed in accordance with the inclusion criteria.30 cases in the control group were given single use of trimetazidine， and 30 cases in the study group were given the combined regimen of atorvastatin and trimetazidine in the study group， and the treatment effect of the two groups were compared.Results The total effective rate of treatment in the study group was 90.91%(28) significantly higher than that of the control group 63.64%(22)，and the two groups were statistically significant (P<0.05).The level of left ventricular end diastolic diameter (LVEDD) and the end systolic diameter(LVESD) in the study group were significantly lower than those in the control group(P<0.05).Conclusion Atorvastatin Combined with trimetazidine can achieve satisfactory results in the treatment of coronary heart disease.It is helpful to improve the cardiac function of the patients and is worthy of clinical application.
【Key words】Atorvastatin；Trimetazidine；Coronary heart disease；Curative effect.
冠心病(coronary atherosclerotic heart disease，CHD)是一組临床常见综合征，病理机制主要为冠状动脉解剖结构或功能异常形成的心肌缺血、梗死。药物干预是治疗本病主要手段，较常规单药治疗方案不同，现阶段强调药理的协同作用，但就具体药物的选择尚无统一标准[1]。本文对60例符合纳入标准的冠心病患者展开对比分析，总结阿托伐他汀联合曲美他嗪治疗冠心病的临床疗效，旨在为临床提供参考，总结如下。
1 资料与方法
1.1 一般资料
对符合纳入标准的2015年4月～2018年1月冠心病患者60例展开对比分析；本组患者入院均行相关检查，符合国际心脏病学会、WHO联合制定的《缺血性心脏病命名及诊断标准》中相关标准；男32例，女28例，年龄46～80岁，平均年龄(61.35±7.41)岁，病程1～20年，平均病程(7.33±0.41)年，体质量53～74 kg，平均(60.15±5.10)kg；两组患者基线资料差异无统计学意义(P>0.05)。
1.2 方法
患者入院后均给予吸氧、扩血管药物、利尿剂等基础治疗；对照组在此基础上给予盐酸曲美他嗪片(泽维尔)(生产厂家：北京万生药业有限责任公司；批准文号：国药准字H20065167)20 mg/次，每日3次；研究组在对照组基础上给予立普妥(阿托伐他汀钙片)(生产厂家：辉瑞制药有限公司；批准文号：国药准字H20051408)
10 mg/次，每日1次。
1.3 疗效判定标准
疗效：依据我国《心血管药物临床试验评价方法的建议》[2]中相关诊断标准评估疗效：显效为患者治疗后超过7 d未感心绞痛，ST段明显回升，导联T波变浅超过50%；有效为患者心绞痛发作频率明显减少，心电图ST段明显改善；无效为达不到上述标准；总有效率=显效率+有效率；
采用心脏彩色超声对患者左室舒张末期内径(LVEDD)与收缩末期内径(LVESD)等心功能指标。, http://www.100md.com(王卫平)